Autologous bone mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes.

[Guest guest]

Hepatology. 2011 May 23. doi: 10.1002/hep.24434. [Epub ahead of print]

Autologous bone mesenchymal stem cell transplantation in liver failure patients

caused by hepatitis B: Short-term and long-term outcomes.

Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL.

Source

From the Department of Infectious Diseases, 3rd Affiliated Hospital of Sun

Yat-sen University, GuangZhou, China.

Abstract

Our study aimed to investigate the short-term efficacy and long-term prognosis

of liver failure patients caused by hepatitis B after a single transplantation

with autologous marrow mesenchymal stem cells (MMSCs). A total of 527 inpatients

with liver failure caused by hepatitis B were recruited and received the same

medical treatments, among whom 53 patients underwent a single transplantation

with autologous MMSCs. A total of 105 patients matched for age, gender, and

biochemical indexes, including alanine aminotransferase (ALT), albumin, total

bilirubin (TBIL), prothrombin time (PT), and Model for End-Stage Liver Disease

(MELD), comprised the control group. A total of 120 ml of bone marrow was

obtained from each patient and then diluted and separated. Then, the MMSC

suspension was slowly transfused into the liver through the proper hepatic

artery. The success rate of transplantation was 100%, without serious side

effects or complications. The levels of ALB, TBIL, PT and the MELD score of

patients in the transplantation group were markedly improved at 2-3 weeks after

transplantation compared with those in the control group. At 192 weeks of

follow-up, there were no dramatic differences in incidence of hepatocellular

carcinoma (HCC) or mortality between the two groups. Additionally, there were no

significant differences in the incidence of HCC or mortality between patients

with and without cirrhosis in the transplantation group. Conclusion: Autologous

MMSC transplantation is safe for liver failure patients caused by chronic

hepatitis B. The short-term efficacy was favorable, but the long-term outcomes

were not markedly improved. In respect to several parameters, this method is

preferable for patients with liver cirrhosis and may have potential for reducing

their incidence of HCC and mortality. (HEPATOLOGY 2011.).

Copyright © 2011 American Association for the Study of Liver Diseases.

PMID: 21608000 [PubMed - as supplied by publisher]

[Guest guest]

Hepatology. 2011 May 23. doi: 10.1002/hep.24434. [Epub ahead of print]

Autologous bone mesenchymal stem cell transplantation in liver failure patients

caused by hepatitis B: Short-term and long-term outcomes.

Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL.

Source

From the Department of Infectious Diseases, 3rd Affiliated Hospital of Sun

Yat-sen University, GuangZhou, China.

Abstract

Our study aimed to investigate the short-term efficacy and long-term prognosis

of liver failure patients caused by hepatitis B after a single transplantation

with autologous marrow mesenchymal stem cells (MMSCs). A total of 527 inpatients

with liver failure caused by hepatitis B were recruited and received the same

medical treatments, among whom 53 patients underwent a single transplantation

with autologous MMSCs. A total of 105 patients matched for age, gender, and

biochemical indexes, including alanine aminotransferase (ALT), albumin, total

bilirubin (TBIL), prothrombin time (PT), and Model for End-Stage Liver Disease

(MELD), comprised the control group. A total of 120 ml of bone marrow was

obtained from each patient and then diluted and separated. Then, the MMSC

suspension was slowly transfused into the liver through the proper hepatic

artery. The success rate of transplantation was 100%, without serious side

effects or complications. The levels of ALB, TBIL, PT and the MELD score of

patients in the transplantation group were markedly improved at 2-3 weeks after

transplantation compared with those in the control group. At 192 weeks of

follow-up, there were no dramatic differences in incidence of hepatocellular

carcinoma (HCC) or mortality between the two groups. Additionally, there were no

significant differences in the incidence of HCC or mortality between patients

with and without cirrhosis in the transplantation group. Conclusion: Autologous

MMSC transplantation is safe for liver failure patients caused by chronic

hepatitis B. The short-term efficacy was favorable, but the long-term outcomes

were not markedly improved. In respect to several parameters, this method is

preferable for patients with liver cirrhosis and may have potential for reducing

their incidence of HCC and mortality. (HEPATOLOGY 2011.).

Copyright © 2011 American Association for the Study of Liver Diseases.

PMID: 21608000 [PubMed - as supplied by publisher]